ERBB2 and breast cancer: Safety and preliminary efficacy of neratinib plus T-DM1 have been demonstrated in patients with HER2-positive breast cancer[35]; clinical trials of neratinib plus antibody–drug conjugates are similarly warranted in the HER2-mutant MBC setting.